The National Comprehensive Cancer Network (NCCN) in 2020 [57], American Society for Transplantation and Cellular Therapy (ASTCT) in 2017 [58] and the European Society for Medical Oncology (ESMO) in 2015 [59] all recommend autoSCT as frontline consolidation as an option for nodal PTCL subtypes PTCL-NOS, AITL, and ALK-negative ALCL. Here, ALK is linked to anaplastic large cell lymphoma.